Panacea Biotec Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Panacea Biotec Ltd trades at ₹549, in a confirmed uptrend and 7 weeks into that stage. That is +30.0% against its own 200-day average. It sits at 80% of a 52-week range of ₹320 to ₹608. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 17 straight weeks.

Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹549 it trades +30.0% versus its 200-day average and sits at 80% of its 52-week range (₹320–₹608).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +518% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 17 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

P/E does not price Panacea Biotec Ltd — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Panacea Biotec Ltd at 4.2× its FY26 revenue of ₹640 Cr.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Panacea Biotec Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

44.8/100 — rank 8 of 10 in Pharma - Others · 65% evidence confidence

Panacea Biotec Ltd scores 44.8 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20.4 + 4.9 + 10 + 9.5 = 44.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Panacea Biotec Ltd reported ₹167 Cr of revenue in the Mar 26 quarter, +25.8% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at −0.2% a year. The last full year, FY26, came in at ₹640 Cr. The last four reported quarters add to ₹640 Cr.

Panacea Biotec Ltd reported ₹167 Cr of revenue in the Mar 26 quarter, +25.8% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at −0.2% a year. The last full year, FY26, came in at ₹640 Cr. The last four reported quarters add to ₹640 Cr.

FY26 revenue came in at ₹640 Cr (+14.5% on the year), capping 10 years at −0.2% compound. The latest quarter (Mar 26) printed ₹167 Cr, +25.8% year on year — the 2nd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +16.7% growth against the decade's −0.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +14.4% over the last 4 quarters against +7.0%/yr over the last 8 — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 1.5% this quarter (+21.8 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Panacea Biotec Ltd's operating margin is 1.5% in the Mar 26 quarter, +21.8 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −29.0% to 17.0%. The current quarter sits inside that band.

Panacea Biotec Ltd's operating margin is 1.5% in the Mar 26 quarter, +21.8 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −29.0% to 17.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 1.5%, +21.8 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −29.0%–17.0%.

Why the margin moved: operating margin went +21.8 pp year on year while gross margin went −6.5 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins held — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Panacea Biotec Ltd posted a net loss of ₹1.0 Cr in the Mar 26 quarter. The full FY26 year was a loss of ₹7.0 Cr. That loss is 0.6% of the quarter's revenue. The same quarter a year earlier lost ₹2.0 Cr. 7 of the last 12 reported quarters were loss-making.

Panacea Biotec Ltd posted a net loss of ₹1.0 Cr in the Mar 26 quarter. The full FY26 year was a loss of ₹7.0 Cr. That loss is 0.6% of the quarter's revenue. The same quarter a year earlier lost ₹2.0 Cr. 7 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹−1.0 Cr, null year on year. On the full year, FY26 printed ₹−7.0 Cr (null).

→ Profit rose — but did the cash follow? Next: 0% of the last 2 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years 0% of Panacea Biotec Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹17.0 Cr of operating cash against ₹−7.0 Cr of profit. After ₹58.0 Cr of capital spending, ₹−41.0 Cr was left as free cash.

FY26: operating cash of ₹17.0 Cr against reported profit of ₹−7.0 Cr, leaving free cash of ₹−41.0 Cr after ₹58.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 0% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 0%: the cash cycle stretched 126 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 126 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 46-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Panacea Biotec Ltd's cash conversion cycle runs 46 days in FY26, up from −80 days in FY21. Capital spending ran ₹183 Cr over the last 3 years. At FY26 sales of ₹640 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹81.0 Cr sits inside the business at any moment.

FY26: debtors at 42 days, inventory at 251 days — roughly 8.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 46 days, looser than FY21's −80.

The full loop: cash goes out to suppliers and production on day 0; stock waits 251 days to sell; customers pay about 42 days after that; and suppliers themselves are paid at 247 days — netting out to the 46-day cycle.

In money terms: at FY26 sales of ₹640 Cr, each day of the cycle holds about ₹1.8 Cr — so the 46-day loop keeps roughly ₹81.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹183 Cr over the last 3 fiscal years against ₹105 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹100 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is −2% and the ROIC − WACC spread is −17.0 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Panacea Biotec Ltd earns a ROCE of −2% in FY26. That is up from a trough of −16% in FY19. Return on invested capital clears the cost of that capital by −17.0 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −1.1% net margin on 0.51× asset turns.

FY26 ROCE is −2%, recovered from a FY19 trough of −16% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): −1.1% net margin × 0.51× asset turns × 1.51× balance-sheet leverage ≈ −0.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: −5.0% − 12.0% = a −17.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.03.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Panacea Biotec Ltd carries total debt of ₹24.0 Cr against shareholder equity of ₹829 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹24.0 Cr against shareholder equity of ₹829 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.03 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 2.0 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 2.0 points of Panacea Biotec Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 2.3% of the company. Domestic institutions moved +1.2 points over the same window, to 2.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +2.0 points over 8 quarters to 2.3%; Domestic institutions: +1.2 points over 8 quarters to 2.3%; Promoters: −1.0 points over 8 quarters to 72.5%.

Why the register moved: foreign institutions drove it (+2.0 points), alongside domestic institutions (+1.2 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Panacea Biotec Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions